Scarica l'app Stockscreener
25.01
0.79%
-0.20
Dopo l'orario di chiusura:
25.06
0.05
+0.20%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché PFE Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$25.21
Aprire:
$25.2
Volume 24 ore:
49.08M
Relative Volume:
1.21
Capitalizzazione di mercato:
$141.84B
Reddito:
$63.63B
Utile/perdita netta:
$8.03B
Rapporto P/E:
17.74
EPS:
1.41
Flusso di cassa netto:
$9.84B
1 W Prestazione:
-4.51%
1M Prestazione:
-4.18%
6M Prestazione:
-14.03%
1 anno Prestazione:
-9.97%
Intervallo 1D:
$24.83
$25.23
Intervallo di 1 settimana:
$24.83
$26.52
Portata 52W:
$24.48
$31.54
Pfizer Inc Stock (PFE) Company Profile
Nome
Pfizer Inc
Settore
Industria
Telefono
(212) 733-2323
Indirizzo
66 HUDSON BOULEVARD EAST, NEW YORK, NY
Confronta PFE con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
25.01 | 141.84B | 63.63B | 8.03B | 9.84B | 1.41 |
|
LLY
Lilly Eli Co
|
821.67 | 738.00B | 45.04B | 10.59B | 414.30M | 11.71 |
|
ABBV
Abbvie Inc
|
202.72 | 358.61B | 56.33B | 4.28B | 17.83B | 2.40 |
|
JNJ
Johnson Johnson
|
163.13 | 344.63B | 88.82B | 14.07B | 18.06B | 5.79 |
|
NVO
Novo Nordisk Adr
|
70.16 | 311.44B | 42.09B | 14.65B | 10.11B | 3.2833 |
|
MRK
Merck Co Inc
|
87.60 | 221.28B | 64.17B | 17.12B | 18.10B | 6.73 |
Pfizer Inc Stock (PFE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-10 | Ripresa | BofA Securities | Neutral |
| 2024-11-15 | Iniziato | Wolfe Research | Underperform |
| 2024-10-25 | Ripresa | Citigroup | Neutral |
| 2024-10-17 | Iniziato | Bernstein | Mkt Perform |
| 2024-08-07 | Aggiornamento | Daiwa Securities | Neutral → Outperform |
| 2024-03-22 | Downgrade | Argus | Buy → Hold |
| 2024-02-23 | Iniziato | Guggenheim | Buy |
| 2024-01-04 | Downgrade | TD Cowen | Outperform → Market Perform |
| 2023-10-20 | Ripresa | UBS | Neutral |
| 2023-10-16 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-07-17 | Reiterato | JP Morgan | Neutral |
| 2023-07-14 | Iniziato | HSBC Securities | Buy |
| 2023-06-29 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2023-05-11 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2023-03-06 | Iniziato | Jefferies | Hold |
| 2023-02-07 | Aggiornamento | Daiwa Securities | Neutral → Outperform |
| 2023-01-26 | Downgrade | UBS | Buy → Neutral |
| 2023-01-17 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2023-01-04 | Downgrade | BofA Securities | Buy → Neutral |
| 2022-12-13 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-11-18 | Iniziato | Credit Suisse | Outperform |
| 2022-05-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2022-04-06 | Ripresa | Morgan Stanley | Equal-Weight |
| 2022-01-05 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2022-01-03 | Reiterato | Bernstein | Mkt Perform |
| 2021-12-20 | Reiterato | Cowen | Outperform |
| 2021-12-17 | Iniziato | Goldman | Neutral |
| 2021-12-13 | Aggiornamento | UBS | Neutral → Buy |
| 2021-12-09 | Iniziato | Wells Fargo | Overweight |
| 2021-11-19 | Iniziato | BMO Capital Markets | Outperform |
| 2021-07-27 | Ripresa | Truist | Buy |
| 2021-05-06 | Downgrade | Mizuho | Buy → Neutral |
| 2021-04-07 | Ripresa | RBC Capital Mkts | Sector Perform |
| 2021-02-04 | Aggiornamento | DZ Bank | Hold → Buy |
| 2020-12-16 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-11-19 | Ripresa | Goldman | Neutral |
| 2020-11-10 | Ripresa | Bernstein | Mkt Perform |
| 2020-10-12 | Downgrade | Atlantic Equities | Overweight → Neutral |
| 2020-09-29 | Iniziato | Berenberg | Hold |
| 2020-06-16 | Iniziato | SVB Leerink | Mkt Perform |
| 2020-02-27 | Iniziato | Barclays | Equal Weight |
| 2020-02-27 | Aggiornamento | Standpoint Research | Hold → Buy |
| 2020-02-06 | Iniziato | Mizuho | Buy |
| 2020-01-07 | Iniziato | RBC Capital Mkts | Outperform |
| 2019-10-17 | Ripresa | BofA/Merrill | Neutral |
| 2019-07-30 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2019-07-30 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2019-06-04 | Ripresa | Morgan Stanley | Overweight |
| 2019-02-20 | Ripresa | Citigroup | Neutral |
| 2019-01-31 | Aggiornamento | Argus | Hold → Buy |
| 2019-01-31 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2019-01-23 | Downgrade | UBS | Buy → Neutral |
| 2018-12-11 | Downgrade | JP Morgan | Overweight → Neutral |
| 2018-11-01 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
Mostra tutto
Pfizer Inc Borsa (PFE) Ultime notizie
Pfizer: Value Play Or Past Its Prime? - Barchart
Pfizer: Value Play or Past Its Prime? - The Globe and Mail
Pfizer Tops Pharma Tax Avoidance, Senate Dems Say - Law360
Pfizer ran big tax dodging scheme: Senator (update) (PFE:NYSE) - Seeking Alpha
Sector Update: Health Care - Marketscreener.com
Pfizer's Bold Tax Maneuver Sparks Controversy - Finimize
Pfizer Avoided Billions in Taxes on Sales, Democrats Say (2) - Bloomberg Tax
UC San Diego Moores Cancer Center Receives $1M Donation from Pfizer for Early Cancer Detection | Newswise - Newswise
May 9th Options Now Available For Pfizer (PFE) - Nasdaq
GSK accuses Pfizer of delaying Covid vaccine result until after US election - Yahoo
Is Pfizer Inc.'s (NYSE:PFE) Recent Price Movement Underpinned By Its Weak Fundamentals? - Yahoo Finance
US prosecutors probe tip about timing of Pfizer's COVID vaccine, WSJ reports - Reuters
Why Pfizer Is My Largest Healthcare Position - MSN
Citi maintains Pfizer stock Neutral with $27 target amid probe By Investing.com - Investing.com Australia
Citi maintains Pfizer stock Neutral with $27 target amid probe - Investing.com
Unpacking Q4 Earnings: Pfizer (NYSE:PFE) In The Context Of Other Branded Pharmaceuticals Stocks - Yahoo Finance
Feds probe tip that Pfizer delayed announcing COVID vaccine’s success until after 2020 election: report - New York Post
Exclusive | U.S. Prosecutors Probe Tip About Timing of Pfizer Vaccine - The Wall Street Journal
Market Today: Pfizer Faces Investigation, Microsoft Scales Back Data Centers - GuruFocus.com
Here's Why Pfizer (PFE) Fell More Than Broader Market - Yahoo Finance
Pfizer Shares Are Down Today: What's Going On? - Benzinga
Pfizer shares dip amid U.S. vaccine probe reports By Investing.com - Investing.com Australia
Pfizer shares dip amid U.S. vaccine probe reports - Investing.com
Pfizer stock drops after U.S. probe on COVID shot (PFE:NYSE) - Seeking Alpha
Pfizer falls after report says US probing tip about timing of COVID vaccine - TradingView
US Prosecutors Investigate Tip on Pfizer Vaccine - Marketscreener.com
US Prosecutors Investigate Tip on Pfizer Vaccine, Wall Street Journal Reports - Marketscreener.com
US Prosecutors Probe Tip About Timing Of Pfizer VaccineWSJ - Marketscreener.com
Moderna, Novavax, and Pfizer shares fall amid U.S. vaccine fund cuts By Investing.com - Investing.com South Africa
Moderna, Novavax, and Pfizer shares fall amid U.S. vaccine fund cuts - Investing.com
Pfizer’s CX Vision: Powered by People, Fueled by Data - CMSWire
ViiV Healthcare Announces Reimbursement for APRETUDE for HIV-1 Pre-Exposure Prophylaxis (PrEP) under the Non-Insured Health Benefits (NIHB) Program - Quantisnow
Pfizer Stock Slips After Report on Vaccine Timing Probe - The Wall Street Journal
Drug Co. Wants Fed. Circ. To Undo Pfizer COVID Patent Win - Law360
Pfizer: Undervalued Defensive Play - Yahoo Finance
Pfizer Is Trading As If It's 2009 Again (NYSE:PFE) - Seeking Alpha
Which is the Healthiest Investment: Merck or PfizerF.A.S.T. GraphsCommentaries - Advisor Perspectives
Broadcom and Crown Castle in the Box have been highlighted as Zacks Bull and Bear of the Day - TradingView
USPTO Finds Claims of Two of Moderna’s mRNA Patents Unpatentable: What’s Next in the Vaccine Wars? - Crowell & Moring LLP
Is Pfizer (PFE) The Best Affordable Stock To Buy According To Hedge Funds? - Insider Monkey
Pfizer Is A Dirt-Cheap High-Yield Stock, But Is It A Buy? - Barchart
China touted its business potential at a meeting with Apple, Pfizer and other US companies - Українські Національні Новини
Pfizer Is a Dirt-Cheap High-Yield Stock, But Is It a Buy? - Zacks Investment Research
Pfizer Inc. (PFE) Stock: Is This Healthcare Giant the Bargain of 2025? - MoneyCheck
Epinephrine Market Is Booming Worldwide 2025-2032 | Pfizer, - openPR
Pfizer Inc. - Britannica
China Courts Apple, Pfizer, Eli Lilly Amid US Pressure, Vice Premier Says Beijing 'Will Continue To Improve The Business Environment' - MSN
China reassures Apple, Pfizer, Cargill, others of business potential - TradingView
China's vice premier reassures Apple, Pfizer, Cargill, others of business potential - TradingView
Is Pfizer Inc. (PFE) The Best Healthcare Dividend Stock to Invest in? - Insider Monkey
Former Pfizer chief scientist joins Immunai’s board of directors - The Jerusalem Post
Pfizer Inc Azioni (PFE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.73%
0.58%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):